
|Videos|October 26, 2016
Results of a Trial Comparing Cabozantinib and Sunitinib in mRCC
Author(s)Toni Choueiri, MD
Toni Choueiri, MD, discusses the results of the ALLIANCE A031203 trial comparing cabozantinib and sunitinib in metastatic renal cell carcinoma (mRCC).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5









































